NCT07491848Recruiting
Oral-Periodontal Evaluation and Assessment of Oral Fluid Biomarkers in Patients With Hepatitis B+D
Oral-Periodontal Evaluation and Assessment of Biomarkers in Oral Fluids in Patients With Hepatitis B+D Treated With Bulevirtide
Source: ClinicalTrials.gov · Last updated 25 Mar 2026
Brief summary (registry, in English)
Periodontal disease is a chronic inflammatory condition associated with systemic diseases, highlighting the concept of periodontal medicine. This study aims to investigate the relationship between periodontal inflammation, oral lesions, and hepatitis B+D infection, with or without bulevirtide treatment. Oral-periodontal clinical parameters and targeted inflammatory biomarkers in saliva and gingival crevicular fluid will be evaluated in three groups: patients with hepatitis B+D receiving bulevirtide, patients with hepatitis B+D not receiving bulevirtide, and healthy controls.
- Status (registry)
- Recruiting
- Study type
- Observational
- Enrollment
- 25 (estimated)
- First submitted
- 13 Mar 2026
- Start date
- 15 Feb 2026
- Primary completion date
- 15 Feb 2027
- Lead sponsor
- Research Center of Periodontal-Systemic Interactions
- Diseases
- Hepatitis B
- NCT number
- NCT07491848
What you commit to
- Study type: Observational
- Planned participants: 25
- From 15 Feb 2026 to the primary completion date, 15 Feb 2027
- 2 sites in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Patients currently receiving other experimental therapies that may affect oral or systemic inflammation.
Other illness
- Patients with other systemic diseases that could influence periodontal health (e.g., uncontrolled diabetes, autoimmune diseases).
- History of oral or periodontal surgery within the last 6 months that could affect measurements.
Other
- Pregnancy or lactation.
- Inability or unwillingness to provide informed consent.
Who the study is looking for
- Adults (≥18 years old) capable of providing informed consent.
- For Hepatitis B+D groups: confirmed hepatitis B and D co-infection.
- Bulevirtide group: receiving bulevirtide therapy as prescribed.
- No Bulevirtide group: not receiving bulevirtide.
- For Healthy Control group: systemically healthy adults without hepatitis B or D infection.
- Willingness to undergo oral-periodontal examination, saliva and gingival crevicular fluid collection, and oral cavity photography.
Age in the registry: 18 years to - · Sex: All · Accepts healthy volunteers
Sites (2)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Clinical Emergency County Hospital Craiova Coordinator of this site? Confirm its status | Craiova | Romania | Recruiting |
| University of Medicine and Pharmacy of Craiova Coordinator of this site? Confirm its status | Craiova | Romania | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.